Enhertu (trastuzumab deruxtecan) has been granted conditional approval in the U.K. for the treatment of adults with inoperable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based ... Read more
An open-label Phase 2 clinical trial will test the safety and efficacy of IRX-2, an experimental immunology-based cancer therapy, in combination with Keytruda (pembrolizumab) and chemotherapy. The study is enrolling ... Read more
Seagen’s Tukysa (tucatinib) has been approved by the European Commission (EC) as part of a triple-combination therapy for people with previously treated advanced or metastatic HER2-positive breast cancer. The EC approved ... Read more
The first participant has been dosed in the Phase 2 clinical trial TENACITY, which is evaluating Ayala Pharmaceuticals‘ investigational therapy AL101 as a treatment for Notch-activated recurrent or metastatic triple ... Read more
After promising results from patients enrolled to date, Atossa Therapeutics halted an Australian Phase 2 clinical trial evaluating its investigative oral therapy Endoxifen in women newly diagnosed with invasive, estrogen ... Read more
Theralink Technologies announced that it has begun testing its new profiling biomarker assay — a test that could potentially provide oncologists with key information about a patient’s specific tumor — ... Read more
A national study is seeking women in the U.S. to help determine the safest and best way to screen for breast cancer, and to improve on current guidelines. It’s being ... Read more
In honor of World Cancer Day on Feb. 4, the Breast International Group (BIG) emphasized the importance of wide-scale cooperation in efforts to advance cancer research. “None of BIG’s achievements ... Read more
The European Commission has conditionally approved Enhertu (trastuzumab deruxtecan) for adults in the EU with inoperable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens. ... Read more
Imagio, Seno Medical Instruments’ non-invasive and radiation-free breast imaging technology, has been approved for commercialization by the Center for Devices and Radiological Health, part of the U.S. Food and Drug Administration ... Read more
// Fill in your MailChimp popup settings below.
// These can be found in the original popup script from MailChimp.
var mailchimpConfig = {
baseUrl: 'mc.us5.list-manage.com',
uuid: '52c64784d386bd00ea57ee792',
lid: 'ea3614260e'
};
// No edits below this line are required
var chimpPopupLoader = document.createElement("script");
chimpPopupLoader.src = '//s3.amazonaws.com/downloads.mailchimp.com/js/signup-forms/popup/embed.js';
chimpPopupLoader.setAttribute('data-dojo-config', 'usePlainJson: true, isDebug: false');
var chimpPopup = document.createElement("script");
chimpPopup.appendChild(document.createTextNode('require(["mojo/signup-forms/Loader"], function (L) { L.start({"baseUrl": "' + mailchimpConfig.baseUrl + '", "uuid": "' + mailchimpConfig.uuid + '", "lid": "' + mailchimpConfig.lid + '"})});'));
jQuery(function ($) {
//document.body.appendChild(chimpPopupLoader);
//$(window).load(function () {
// document.body.appendChild(chimpPopup);
});
});
